Evaluation of Carotid IMT and Atherogenic Risk Factors in Patients With Cerebrotendinous Xanthomatosis (CTX)
Recruitment status was Recruiting
The aim of the proposed study is to evaluate the risk for cardiovascular disease and 'atherogenic' features of the serum in CTX and to determine preclinical atherosclerosis. The study will include an extensive assessment of lipoprotein profile and carotid artery intima-media thickness (cIMT) measurement.
Lipid and lipoprotein profiles will include novel tests such as direct measurements of apolipoprotein A1,B,C2,C3 plasma levels, lipoprotein (a) levels, highly sensitive C-reactive protein levels and PLAC test that measures the levels of lipoprotein-associated phospholipase A2-a vascular-specific inflammatory enzyme implicated in the formation of atherosclerosis
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Evaluation of Carotid IMT and Atherogenic Risk Factors in Patients With Cerebrotendinous Xanthomatosis|
- Predisposition of CTX patients for pro-atherogenic features as evaluated by lipid and lipoproteins plasma profiles, and blood chemical assessment. Preclinical atherosclerosis in CTX patients as determined by Carotid artery Intima-media thickness 1. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
The predisposition of the serum of CTX patients to be pro-atherogenic will be evaluated by detailed lipid and lipoproteins plasma profiles, and blood chemical assessment of specific inflammatory pro-atherogenenic features.
IMT Presence of preclinical atherosclerosis will be determined by Carotid artery Intima-media thickness as a marker of risk for cardiovascular disease.
Biospecimen Retention: Samples Without DNA
Lipid and lipoprotein profiles
|Study Start Date:||August 2010|
|Estimated Study Completion Date:||June 2015|
|Estimated Primary Completion Date:||May 2013 (Final data collection date for primary outcome measure)|
Biological: Blood tests
Other Name: CTX Group
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01613898
|The Bert W. Strassburger Lipid Center||Recruiting|
|Tel Hashomer, Israel, 52621|
|Contact: tamar luvish, BSN 972-35303492 firstname.lastname@example.org|
|Principal Investigator: Hofit Cohen, Dr.|
|Principal Investigator:||Hofit Cohen, MD||The Bert W. Strassburger Lipid Center|